Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-02-14 4:21 pm Sale | 13G | CYTEIR THERAPEUTICS INC CYT | BAKER BROS. ADVISORS LP | 0 0% | -2,492,118 (Position Closed) | View |
| 2024-02-14 4:21 pm Purchase | 13G | CERUS CORP CERS | BAKER BROS. ADVISORS LP | 19,497,203 10.8% | 395,327 (+2.07%) | View |
| 2024-02-14 4:21 pm Purchase | 13G | HOOKIPA PHARMA INC HOOK | BAKER BROS. ADVISORS LP | 8,148,985 9.99% | 4,673,450 (+134.47%) | View |
| 2024-02-14 4:21 pm Purchase | 13G | IMMATICS N V IMTX | BAKER BROS. ADVISORS LP | 5,838,853 6.9% | 651,772 (+12.57%) | View |
| 2024-02-14 4:21 pm Purchase | 13G | MONTE ROSA THERAPEUTICS INC CO GLUE | BAKER BROS. ADVISORS LP | 4,916,095 9.8% | 4,916,095 (New Position) | View |
| 2024-02-14 4:21 pm Purchase | 13G | NURIX THERAPEUTICS INC NRIX | BAKER BROS. ADVISORS LP | 4,952,452 9.99% | 150,498 (+3.13%) | View |
| 2024-02-14 4:21 pm Sale | 13G | OPTHEA LTD SPONSORED ADR OPT | BAKER BROS. ADVISORS LP | 28,100,345 4.2% | -3,527,499 (-11.15%) | View |
| 2024-02-14 4:21 pm Purchase | 13G | RHYTHM PHARMACEUTICALS INC RYTM | BAKER BROS. ADVISORS LP | 6,398,365 10.8% | 43,757 (+0.69%) | View |
| 2024-02-14 4:21 pm Purchase | 13G | SAGIMET BIOSCIENCES INC SER A SGMT | BAKER BROS. ADVISORS LP | 1,456,518 6.8% | 1,456,518 (New Position) | View |
| 2024-02-14 4:21 pm Sale | 13G | ASCENDIS PHARMA A/S SPONSORED ASND | BAKER BROS. ADVISORS LP | 0 0% | -4,954,855 (Position Closed) | View |
| 2024-02-14 4:21 pm Purchase | 13G | ATHIRA PHARMA INC ATHA | BAKER BROS. ADVISORS LP | 3,153,807 8.3% | 3,153,807 (New Position) | View |
| 2024-02-14 4:21 pm Sale | 13G | BIOCRYST PHARMACEUTICALS INC BCRX | BAKER BROS. ADVISORS LP | 10,204,089 4.98% | -8,980,705 (-46.81%) | View |
| 2024-02-14 4:21 pm Purchase | 13G | BIOMEA FUSION INC BMEA | BAKER BROS. ADVISORS LP | 2,108,949 5.9% | 4,390 (+0.21%) | View |
| 2024-02-14 4:21 pm Purchase | 13G | KALA BIO, INC. KALA | BAKER BROS. ADVISORS LP | 269,213 9.99% | 88,300 (+48.81%) | View |
| 2024-02-12 4:10 pm Purchase | 13G | BICYCLE THERAPEUTICS PLC SPONS BCYC | BAKER BROS. ADVISORS LP | 4,823,598 12.8% | 4,823,598 (New Position) | View |
| 2024-02-01 5:25 pm Sale | 13D | IMMUNOCORE HLDGS PLC ADS IMCR | BAKER BROS. ADVISORS LP | 2,452,871 4.99% | -2,232,819 (-47.65%) | View |
| 2024-01-10 4:58 pm Purchase | 13G | SERA PROGNOSTICS INC SERA | BAKER BROS. ADVISORS LP | 5,434,399 17.9% | 5,434,399 (New Position) | View |
| 2024-01-10 4:57 pm Purchase | 13G | REPLIMUNE GROUP INC REPL | BAKER BROS. ADVISORS LP | 9,545,336 16.2% | 3,777,109 (+65.48%) | View |
| 2024-01-10 4:52 pm Purchase | 13G | ATRECA INC BCEL | BAKER BROS. ADVISORS LP | 7,677,982 19.99% | 4,145,222 (+117.34%) | View |
| 2024-01-10 4:52 pm Purchase | 13G | KYMERA THERAPEUTICS INC KYMR | BAKER BROS. ADVISORS LP | 5,995,928 10.8% | 3,116,103 (+108.20%) | View |